CNC

Over the past six months (April to October 2026), Centene's stock was influenced by several events: Q1 2026 earnings reported on April 28, 2026, showed an adjusted diluted EPS of $3.11, surpassing expectations due to strong Medicaid and Medicare performance. The company held its Annual General Meeting on May 12, 2026. On July 28, 2026, Q2 2026 results significantly beat analyst estimates with a GAAP diluted EPS of $2.19 and an adjusted diluted EPS of $2.51, leading to an increase in full-year 2026 EPS guidance and a stock price rebound. Centene shares reached a 52-week high near $69.63, followed by a pullback attributed to profit-taking. The company participated in the Deutsche Bank Healthcare Summit on September 16, 2026, and reaffirmed its full-year 2026 EPS guidance in a September 16 SEC filing. Centene announced a restructuring of its Medicare Advantage business for 2027, discontinuing certain offerings and exiting Hawaii, Oklahoma, and Tennessee due to unfavorable economics and medical-cost pressure. Approximately $15 million in insider stock selling was reported. As of September 30, 2026, Centene's share price was $62.12, marking a 74.10% increase over the preceding year, and closed at $65.36 on October 9, 2026.